5.5 million people in the Arab world’s only Arabic-French-English trilingual research environment; the American University of Beirut’s NIH-affiliated American-standard medical research, the Druze population’s unique founder-effect pharmacogenomics, and the world’s most intensively studied crisis-compound mental health research cohort.
Lebanon is a parliamentary republic of approximately 5.5 million citizens; occupying 10,452 km² of the eastern Mediterranean Levant, bordered by Syria to the north and east and Israel to the south; whose research profile is defined less by its geographic size or population than by an extraordinary density of internationally credentialed research institutions, a trilingual educated class (Arabic, French, English) unique in the Arab world, and one of the highest scientific publication rates per capita of any country in the MENA region. Beirut; the capital and cultural heart, approximately 2.2 million in the metropolitan area; hosts Lebanon’s entire major research infrastructure: the American University of Beirut Medical Center (AUBMC), Hôtel-Dieu de France (USJ), the Lebanese American University Medical Center, Saint George Hospital University Medical Center, and Clemenceau Medical Center. Lebanon’s research identity is anchored by an institutional configuration that no other Arab country replicates: the American University of Beirut (AUB); founded in 1866, accredited by the New England Association of Schools and Colleges (NEASC) under American academic standards, and conducting NIH-funded research through the same institutional research governance frameworks as US academic medical centres; provides a research environment in the Arab Levant whose data quality, IRB standards, and investigator training are directly comparable to those of a US academic medical centre, in a patient population whose Levantine Arab genetics, confessional community genetic diversity, and compound-crisis mental health burden create research opportunities unavailable in Boston or Baltimore. Lebanon also hosts approximately 1.5 million Syrian refugees (one of the world’s highest per-capita refugee populations, concentrated in the Bekaa Valley, northern Lebanon, and the Beirut periphery) whose health research profile; including PTSD, conflict-disrupted NCD management, and infectious disease burden; Lebanon’s research institutions have studied more comprehensively than any other country in the series. The Druze community of Mount Lebanon (~250,000 in Lebanon, concentrated in the Chouf mountains) represents one of the world’s most studied endogamous genetic isolates, whose unique rare disease pharmacogenomics; characterised extensively by AUB’s genetics research programme; create a research opportunity with no equivalent in any other Arab research market.
Lebanon’s research context requires candid acknowledgment of the economic and institutional crisis that has severely disrupted the country since 2019: the collapse of the banking sector (depositors losing access to savings), hyperinflation of the Lebanese Pound (LBP) from the historic 1,500 LBP/USD peg to 90,000–100,000+ LBP/USD in the parallel market, the August 4, 2020 Beirut port explosion (one of the largest accidental non-nuclear explosions in history, killing 218 people and devastating the city’s port district; including direct blast damage to AUBMC and surrounding hospitals), and persistent political deadlock. For sponsors, this context is operationally material: trial budgets must be managed in USD cash (Lebanon has effectively dollarised informally), financial logistics require non-Lebanese banking channels, and institutional function at MOH and public hospitals has been variably disrupted. What is equally important to state is that AUB and the major private research hospitals have continued to function throughout this crisis; sustained by endowment, diaspora philanthropy, international grants, and direct USD-denominated operations; producing internationally published research through the Beirut blast period and beyond. Clinical trials in Lebanon are authorised by the Ministry of Public Health (MOPH) under WHO GCP and ICH GCP E6(R2)-aligned regulations, with ethics review conducted through institutional IRBs at major research hospitals; AUB’s IRB is one of the most internationally credentialed IRBs in the Arab world, having operated to US research ethics standards since the 1990s.
Lebanon’s 5.5 million citizens are predominantly Levantine Arab; but Lebanon’s most distinctive demographic characteristic is its confessional diversity: 18 officially recognised religious sects (including Shia Muslim, Sunni Muslim, Maronite Christian, Greek Orthodox, Druze, Armenian Apostolic, Greek Catholic, Alawite, and numerous smaller communities) whose historical endogamy over centuries has created multiple genetically distinct sub-populations within a territory smaller than Connecticut. This sectarian genetic structure gives Lebanon a pharmacogenomic complexity that dramatically exceeds what its total population of 5.5 million would suggest: the Maronite Christian communities of Mount Lebanon, the Greek Orthodox communities of Koura, Hasbaya, and the Bekaa, the Armenian community of Bourj Hammoud (descendants of 1915 genocide refugees; a highly endogamous founder population), and the Druze communities of the Chouf and Hasbaya each carry distinct pharmacogenomic profiles shaped by centuries of religious-sectarian endogamy and geographic isolation in Lebanon’s mountain valleys. The Druze; approximately 250,000 in Lebanon, concentrated in the Chouf District of Mount Lebanon, the Matn, and Hasbaya; are the most extensively studied of these communities: an endogamous religious minority that does not accept converts and has historically married almost exclusively within the community, creating over several hundred years a genetic isolate whose rare disease burden has been characterised in landmark publications by AUB, Hadassah, Tel Aviv University, and Columbia University researchers; specific Druze-community conditions include LGMD2B (limb-girdle muscular dystrophy type 2B, caused by dysferlin mutations, with among the world’s highest prevalence rates in Lebanese Druze), cardiomyopathy associated with LMNA mutations, and specific retinitis pigmentosa variants. The Lebanese Armenian community (~100,000) carries founder-effect conditions from the post-genocide refugee population bottleneck. Lebanon’s Syrian refugee population (~1.5 million) and Palestinian refugees (long-established communities in camps, approximately 200,000–300,000) add further demographic complexity. Lebanon’s educated professional class is comprehensively trilingual; Arabic as the native language, French from the French-mandate educational tradition (1920–1943) preserved in the Francophone university system (USJ, Notre Dame University, others), and English as the dominant academic and research language at AUB, LAU, and throughout the biomedical research community; creating the only Arab research market where protocols, investigator communications, regulatory submissions, and patient-facing materials can all be produced natively in the language of any major pharmaceutical company’s regulatory affairs team.
Lebanon’s disease burden is shaped by a rapid NCD transition overlaid with extraordinary levels of conflict-related and crisis-induced mental health disorder. Cardiovascular disease leads mortality (~38% of deaths); hypertension is extremely prevalent (~30% of adults), coronary artery disease and heart failure are growing rapidly with dietary change and sedentary urbanisation, and tobacco use (including both cigarette smoking and narghile/shisha water pipe; the cultural centrepiece of Lebanese social life) runs at approximately 40% of adults overall with narghile particularly prevalent. Cancer is the second leading cause of death; Lebanon has some of the Arab world’s highest cancer rates for a country of its income level; possibly reflecting environmental factors, tobacco exposure, and population ageing; with breast cancer most common in women, colorectal cancer growing, and lung cancer elevated by tobacco. Mental health disorders; PTSD, depression, anxiety, and substance use disorders; constitute Lebanon’s most globally distinctive disease burden and research opportunity: decades of civil war, Israeli invasions, Hezbollah-Israel conflicts, political assassinations, the Syrian refugee crisis, the 2019 economic collapse, and the 2020 Beirut port explosion have produced documented rates of PTSD among Lebanese civilians that are among the highest of any country studied outside active conflict zones; AUB’s Institute for Disaster Mental Health Research, LAU’s School of Medicine researchers, and the Lebanese University’s mental health programmes have published the most comprehensive body of Arabic-language-population crisis mental health research in the peer-reviewed literature. Type 2 diabetes (~12–15% of adults) and its metabolic comorbidities are a significant and growing NCD burden. Respiratory disease; COPD, asthma, and narghile-associated lung disease; carries a specific Lebanese tobacco-pattern burden.
The American University of Beirut Medical Center; the Arab world’s most internationally credentialed research institution and its Druze genetics programme: The American University of Beirut (AUB), founded in 1866 by American Protestant missionaries and accredited since by the New England Association of Schools and Colleges (NEASC) under the same institutional standards that govern Harvard, Yale, and MIT, is the Arab world’s oldest American-standard university; and its Medical Center (AUBMC) is the most internationally credentialed academic research hospital between Tel Aviv and Karachi. AUB’s research programme is funded through NIH grants (multiple active R01, R21, and programme project grants), WHO research awards, Wellcome Trust support, and major international philanthropic foundations; producing research output published in the New England Journal of Medicine, Lancet, JAMA, Cancer Research, and other tier-1 journals that is subject to the same peer review and methodological scrutiny as research from Johns Hopkins or Mayo Clinic. The implications for clinical trial sponsors are direct: AUBMC’s institutional IRB operates under US research ethics standards, its GCP training is conducted to ICH E6(R2) and FDA inspection-ready standards, and its data management systems produce trial documentation whose quality is directly comparable to US academic medical centre output; without the “non-ICH country” data quality questions that regulatory reviewers sometimes raise about research conducted at institutions without sustained US-standard governance frameworks. AUB’s AUBIO Biobank; one of the Arab world’s very few properly governed, ethics-approved, and internationally connected population biobanks; stores biological samples from Lebanese citizens with full ethics consent, enabling retrospective pharmacogenomic sub-studies and biomarker analyses within commercial trial programmes that most other Arab research sites cannot offer. AUB’s Druze genetics research programme has characterised in peer-reviewed publications the pharmacogenomics of Lebanon’s Druze community; specifically the dysferlin (DYSF) gene mutations causing limb-girdle muscular dystrophy type 2B (LGMD2B) at the highest prevalence rates in the world among Lebanese Druze, LMNA cardiomyopathy variants, and multiple novel recessive conditions described for the first time in Druze pedigrees through AUB’s genetics clinic; creating a rare disease pharmacogenomics research platform for the Druze genetic isolate that is only partially paralleled by Israeli research (where ~150,000 Israeli Druze provide a smaller comparable cohort through Rambam Medical Center and Ben-Gurion University). For rare disease drug developers whose indications include conditions identified in the Druze genetic isolate, AUBMC is the world’s most important single research institution for accessing Lebanese Druze patients within an American-standard clinical research environment.
Lebanon’s research proposition is built on depth rather than scale: a country of 5.5 million that produces research impact disproportionate to its population through AUB’s American-standard institutional infrastructure, the only trilingual (Arabic-French-English) research workforce in the Arab world, the world’s most intensively studied compound-crisis mental health population, and a confessional-community genetic diversity; including the globally significant Druze genetic isolate; that no other Arab research market provides. Sponsors must plan carefully for the operational context of Lebanon’s ongoing financial crisis; those who do access one of the Arab world’s most scientifically sophisticated and internationally connected research environments.
MOPH (Ministry of Public Health) clinical trial authorisation under WHO GCP and ICH GCP E6(R2) standards; AUB IRB; the most internationally credentialed IRB in the Arab world, operating to US research ethics standards since the 1990s; USJ CEHDF ethics committee for Francophone oncology and medical programmes; institutional IRBs at all major private research hospitals; English, French, and Arabic all accepted in regulatory submissions; MOPH approval timelines historically 1–3 months for standard Phase II–III applications; AUB’s NIH-funded research framework provides US academic medical centre GCP documentation standards directly without bridging requirement concerns.
Lebanon operates on a de facto USD cash economy following the LBP collapse; trial budgets should be planned and managed entirely in USD through non-Lebanese banking channels; per-patient costs are very competitive given Lebanon’s crisis-driven cost deflation; USD-denominated operations at AUB, USJ, and major private hospitals provide currency stability for sponsor budgets; Beirut Rafik Hariri International Airport (direct connections to Paris, London, Frankfurt, Dubai, Cairo, and major MENA hubs); central Beirut research cluster is compact (all major sites within 5–10 km); diaspora-connected investigator community with US and European research relationship networks; careful financial management planning is required; sponsors should engage experienced MENA CROs with Lebanon-specific operational expertise.
5.5M with 18-sect confessional genetic structure creating multiple endogamous founder populations; Druze community (~250,000; world’s most studied Arab genetic isolate; LGMD2B highest prevalence globally; LMNA cardiomyopathy; novel recessive conditions characterised at AUB); Armenian community (~100,000; post-genocide founder effect); Maronite and Greek Orthodox community genetics (distinct Levantine Mediterranean pharmacogenomics); world’s most intensively studied compound-crisis PTSD and mental health population; Syrian refugee population for conflict-health research; T2D 12–15% of adults; very high narghile tobacco use creating distinctive respiratory disease burden; AUBIO Biobank for retrospective pharmacogenomic sub-studies.
AUB Medical Center; NEASC-accredited American-standard research hospital; NIH-funded; AUBIO Biobank; one of the Arab world’s best-equipped IRBs; consistently ranked top 5 hospitals in the Arab world; Hôtel-Dieu de France (USJ); leading Francophone academic hospital; French oncology and cardiology research tradition; LAU Medical Center (Rizk Hospital); American-accredited; Saint George Hospital University Medical Center (Balamand University); Clemenceau Medical Center; JCI-accredited private; trilingual investigator community (Arabic native; French and English research-fluent); the only Arab research market where all three pharmaceutical research languages are native investigator languages; Lebanese diaspora research networks connecting AUBMC to Harvard, Johns Hopkins, INSERM, and other international institutions.
Mental health; PTSD, depression, anxiety, and substance use disorders; is Lebanon’s most globally distinctive and scientifically irreplaceable research pillar, and the one that makes Lebanon unique across the entire GCT series: no other country in the Arab world, and very few globally, has subjected its civilian population to the compound mental health burden of a 15-year civil war (1975–1990), multiple Israeli military incursions (1982, 2006), targeted political assassinations, the 2015 garbage crisis, the 2019 economic collapse, the COVID-19 pandemic, and the August 4, 2020 Beirut port explosion; and documented that burden through the internationally credentialed research infrastructure of AUB, LAU, and their collaborating international institutions. AUB’s Institute for Disaster Mental Health Research, the Institute for Health and Human Rights, and multiple AUB Faculty of Medicine research groups have published peer-reviewed studies on blast-related PTSD (the 2020 explosion created the world’s most comprehensively studied post-blast civilian trauma cohort; dozens of published studies within 24 months), compound-crisis depression, substance use disorder in crisis contexts, and refugee mental health; creating a Lebanese mental health research literature of global reference significance for sponsors developing anxiolytics, antidepressants, PTSD medications, and substance use disorder therapeutics who need Arabic-speaking Levantine population data from a crisis-affected civilian cohort. Cardiovascular disease is Lebanon’s most commercially accessible research pillar; the leading cause of mortality with very high hypertension prevalence and a growing coronary artery disease burden anchored by AUBMC’s internationally connected cardiac programme and Hôtel-Dieu de France’s cardiology department, both operating to French and American academic standards that create cardiovascular trial data acceptable to both FDA and EMA without the bridging concerns occasionally raised about less-credentialed Arab sites. Rare and genetic diseases anchored by the Druze pharmacogenomics programme; AUB’s unique research on LGMD2B (dysferlin mutations), LMNA cardiomyopathy, and novel Druze rare conditions; is Lebanon’s most globally irreplaceable research niche; for sponsors developing rare disease therapies where Druze patients are a target population or a pharmacogenomically distinct reference group, AUB provides the world’s only large-scale, American-standard research infrastructure in the community. Respiratory medicine, including COPD and narghile water pipe-specific lung disease (Lebanon’s high narghile smoking rates create a distinctive respiratory research population whose pulmonary pathology differs in specific ways from cigarette-only-smoking populations), is an emerging specialty. Oncology through Hôtel-Dieu de France, AUBMC, and the National Cancer Institute Lebanon, metabolic disease, and transplantation (AUB’s active transplantation programme) complete a research portfolio whose scientific depth is remarkable for a country of 5.5 million.
Beirut concentrates all of Lebanon’s major research hospitals within a remarkably compact geography; AUBMC, Hôtel-Dieu de France, LAU Medical Center, Saint George Hospital University Medical Center, and Clemenceau Medical Center are all within a 6–7 km radius in Beirut’s western and eastern districts, creating a research cluster whose density of internationally credentialed institutions per square kilometre is unmatched in the Arab world. Outside Beirut, institutions in Tripoli (north Lebanon), the Bekaa Valley, and the southern coast extend Lebanese research access to the Syrian refugee concentrations, Druze mountain communities, and Shia southern populations whose health profiles differ substantially from Beirut’s urban professional catchment.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | AUB Medical Center (AUBMC) | Beirut (Hamra) | The Arab world’s most internationally credentialed academic medical research hospital; operated by the American University of Beirut (NEASC-accredited, 1866), NIH-funded, publishing in NEJM, Lancet, JAMA, and other tier-1 journals; with Phase I–IV commercial and investigator-initiated trial activity across cardiovascular, oncology, rare and genetic diseases (including the world’s primary Druze genetics research programme), mental health (PTSD, depression, substance use disorders), haematology, transplantation, and internal medicine; AUBMC’s institutional IRB; operating to US research ethics standards with an independent review process directly comparable to US academic medical centre IRBs; provides the most internationally recognised ethics governance of any Arab research hospital; AUBIO Biobank, the Arab world’s most properly governed research biobank, enables retrospective pharmacogenomic sub-studies within commercial trial programmes; the definitive institutional partner for any sponsor whose programmes require AUB’s specific combination of American-standard research governance, Arabic-speaking Levantine patient population, and access to the Druze genetic isolate through AUB’s established Chouf mountain community clinical outreach programme. |
| 02 | Hôtel-Dieu de France (HDF); Université Saint-Joseph | Beirut (Achrafieh) | Lebanon’s premier Francophone academic hospital; affiliated with Université Saint-Joseph de Beyrouth (USJ, founded 1875 by Jesuits; French accreditation connections) and consistently ranked among Lebanon’s highest-quality hospitals; with Phase II–IV commercial research activity across oncology (one of Lebanon’s most active cancer research programmes, with Francophone oncology cooperative group connections), cardiovascular, neurology, haematology, and internal medicine; Hôtel-Dieu de France’s CEHDF ethics committee provides French-language ethics review aligned with French research ethics conventions for Francophone pharmaceutical company sponsors; the hospital’s primarily Francophone-Christian catchment from Beirut’s eastern Maronite and Greek-Catholic districts provides research access to a distinct Lebanese confessional-genetic demographic from the Hamra-district Arab Muslim and secular populations that dominate AUBMC’s catchment; an essential site for sponsors whose programmes use both US and French academic medical centre reference standards and who need to activate both AUB (anglophone-American) and HDF (Francophone) parallel institutional pathways in Beirut. |
| 03 | LAU Medical Center; Rizk Hospital | Beirut (Hamra) | The primary teaching hospital of Lebanese American University (LAU); another NEASC-accredited American university in Beirut, providing a second American-standard academic medical research environment complementary to AUBMC; with Phase II–III commercial research activity across oncology (LAU’s cancer programme has been particularly active in breast cancer and gastrointestinal oncology research), cardiovascular, and internal medicine; LAU Medical Center’s commitment to Lebanese mental health research; including post-Beirut-blast PTSD studies, refugee mental health programmes, and substance use disorder research; has produced internationally published papers in Lancet Psychiatry, PLOS ONE, and other journals; LAU’s research programme benefits from its American accreditation’s IRB standards and its Lebanese diaspora network connections (LAU’s alumni and faculty include Lebanese-Americans at major US medical centres) that facilitate international research collaborations. |
| 04 | Saint George Hospital University Medical Center (SGHUMC) | Beirut (Achrafieh) | Beirut’s third major academic research hospital; affiliated with the University of Balamand (a Greek Orthodox institution with French and international academic connections) and one of Lebanon’s oldest and most respected hospitals; with Phase II–III research activity across cardiovascular, oncology, internal medicine, and nephrology; Saint George Hospital’s Achrafieh location serves Beirut’s Greek Orthodox and broader eastern Christian communities whose distinct Lebanese confessional-genetic profile creates pharmacogenomic research access to Levantine Mediterranean Christian genetic ancestry that is not the dominant demographic in AUB’s more heterogeneous Hamra catchment; Saint George Hospital University Medical Center’s affiliation with the University of Balamand and its connections to Greek Orthodox academic networks in Greece, Cyprus, and the wider Orthodox diaspora create international research partnership channels that complement the American-standard channels of AUB and LAU. |
| 05 | Clemenceau Medical Center (CMC) | Beirut (Clemenceau) | One of Beirut’s most internationally recognised private hospitals; JCI-accredited, located in the Clemenceau district between Hamra and Achrafieh; with Phase II–III commercial research activity across cardiovascular, oncology, metabolic disease, and internal medicine; Clemenceau Medical Center’s JCI accreditation and established multinational pharmaceutical company research relationships create a private hospital research environment whose quality management documentation standards and experienced research coordination team attract sponsors requiring Beirut private-sector research access beyond the university-affiliated public hospital networks; CMC’s patient catchment from Beirut’s mixed residential and diplomatic district; including Lebanese professionals, expatriate residents, and Arab medical tourists visiting Beirut (Lebanon retains significant medical tourism from Gulf countries and Iraq despite the economic crisis); provides enrollment access to a socioeconomic and nationally diverse patient demographic that differs from the primarily Lebanese-national public hospital catchments. |
| 06 | Rafik Hariri University Hospital (RHUH) | Beirut (Haret Hreik) | Lebanon’s primary public academic hospital; named after former Prime Minister Rafik Hariri and serving as the government’s national referral centre for complex cases and infectious disease; affiliated with the Lebanese University (LU) Faculty of Medicine and conducting Phase II–III research in infectious disease, internal medicine, and cardiovascular; RHUH’s location in Haret Hreik in Beirut’s southern suburbs; a predominantly Shia Muslim area that forms part of the Dahieh (southern suburb) demographic; provides research access to a distinct Lebanese confessional-community patient population whose genetic profile and healthcare utilisation patterns differ from those of Hamra and Achrafieh’s Christian-majority private hospital catchments; RHUH’s role as Lebanon’s national COVID-19 referral hospital during the pandemic produced internationally published COVID-19 clinical research, demonstrating the hospital’s capacity for rapid protocol implementation in crisis conditions. |
| 07 | Makassed General Hospital | Beirut (West Beirut) | Beirut’s largest Islamic welfare society hospital; operated by the Maqased Charitable Islamic Society and serving West Beirut’s predominantly Sunni Muslim community; with Phase II–III research activity across internal medicine, cardiovascular, paediatrics, and mental health; Makassed General Hospital’s Sunni Muslim community catchment provides research access to a distinct Lebanese confessional-genetic demographic; including families with origins in Tripoli, the Bekaa Valley, and southern Sunni communities; whose pharmacogenomic profile and healthcare-seeking patterns differ from the Shia Dahieh communities of RHUH or the Christian East Beirut communities of Hôtel-Dieu de France; Makassed’s mental health programme has been active in refugee mental health research, particularly given the hospital’s geographic proximity to Palestinian refugee camps (Shatila and Sabra) and its historical role serving displaced Lebanese and refugee communities. |
| 08 | LAU Medical Center; Saint John’s Hospital (HMSJ) | Dora | LAU Medical Center’s northern Beirut campus; operating Saint John’s Hospital in Dora, the industrial suburb northeast of Beirut; and providing Phase II–III research access to the Armenian community concentration in Bourj Hammoud adjacent to Dora; Lebanese Armenians (~100,000 in Lebanon) represent one of the world’s most significant post-genocide founder-effect populations; descendants of survivors of the 1915 Armenian Genocide who settled in Lebanon after 1915–1923, forming a highly endogamous community in Bourj Hammoud whose genetic bottleneck has created elevated prevalence rates of specific rare conditions that AUB and Lebanese Armenian community organisations have begun characterising; LAU’s Saint John’s Hospital serves this community’s healthcare needs and provides a research access point for sponsors developing rare disease therapies where Armenian founder-effect genetics are a pharmacogenomically relevant consideration. |
| 09 | Middle East Institute of Health | Bsalim | A major private hospital in Bsalim; in the Metn district of Mount Lebanon, northeast of Beirut; with Phase II–III commercial research activity across cardiovascular, oncology, and internal medicine; the Middle East Institute of Health’s Metn location provides research access to the Metn district’s predominantly Christian (Maronite and Greek Catholic) mountain communities whose distinct Lebanese confessional-genetic background and proximity to the Chouf mountains; where Lebanon’s Druze communities are concentrated; create research access to the Lebanese Druze-Christian Metn demographic corridor that approaches AUB’s Chouf outreach catchment from a Metn-side private hospital perspective; a well-equipped private hospital whose research office has managed commercial Phase II–III programmes across multiple therapeutic areas. |
| 10 | Notre Dame des Secours University Hospital | Jbeil (Byblos) | The university teaching hospital of Notre Dame University (NDU); a pontifical Catholic university affiliated with the Holy Spirit University of Kaslik; located in Jbeil (ancient Byblos), one of the world’s oldest continuously inhabited cities on Lebanon’s northern coast, and serving the Jbeil district’s predominantly Maronite Christian mountain and coastal communities; Phase II–III research activity across cardiovascular, internal medicine, and oncology; Notre Dame des Secours University Hospital’s northern coastal Maronite patient catchment; from the Jbeil, Batroun, and Koura communities whose distinctive Levantine Mediterranean Christian genetic ancestry has been maintained through high sectarian endogamy rates in Lebanon’s northern mountain villages; provides research access to a pharmacogenomically distinct Lebanese confessional-community sub-population that complements Beirut’s more demographically mixed urban patient catchments; its NDU academic affiliation and Catholic university international connections create research partnership channels with Catholic universities in France, Italy, and North America. |
| 11 | Al-Nini Hospital (Tripoli) | Tripoli | Tripoli’s major private hospital; serving Lebanon’s second-largest city (~250,000 population; predominantly Sunni Muslim; located 85 km north of Beirut near the Syrian border); with Phase II–III research activity across internal medicine, cardiovascular, and infectious disease; Al-Nini Hospital’s Tripoli location provides research access to northern Lebanon’s demographically distinct patient population; including Sunni Muslim communities from Tripoli’s historic port districts and the Akkar rural northern governorate; and is strategically positioned near the Syrian refugee concentrations of northern Lebanon’s Akkar and Bekaa border areas, where mental health, conflict-related NCD disruption, and infectious disease burden (including cutaneous leishmaniasis transmission from Syrian refugee-associated Phlebotomus sandfly spread) create refugee health research access complementary to Beirut’s urban research sites; northern Lebanon’s distinct Sunni and minority Christian communities provide a pharmacogenomically different Lebanese patient demographic from Beirut’s more heterogeneous urban mix. |
| 12 | Hôpital du Sacré-Cœur (Jdeideh) | Jdeideh | A major private hospital in Jdeideh; the northern Beirut suburb adjacent to Bourj Hammoud’s Armenian quarter; with Phase II–III research activity across psychiatry, cardiovascular, and internal medicine; Hôpital du Sacré-Cœur’s psychiatric department; one of Lebanon’s most active inpatient and outpatient mental health treatment centres; provides research access to a large psychiatric patient population whose compound-crisis mental health burden (PTSD, depression, anxiety disorders, schizophrenia) reflects the full severity of Lebanon’s population-level mental health crisis; its Jdeideh location near the Armenian Bourj Hammoud community creates dual research access; to the psychiatric patient populations whose post-blast and post-crisis PTSD makes Lebanon’s mental health programme distinctive globally, and to the Lebanese Armenian community’s founder-effect genetic characteristics that are accessible through Sacré-Cœur’s Armenian-community catchment in Bourj Hammoud. |
The Arab world’s most internationally credentialed academic medical research hospital; operated by the American University of Beirut (NEASC-accredited, 1866), NIH-funded, publishing in NEJM, Lancet, JAMA, and other tier-1 journals; with Phase I–IV commercial and investigator-initiated trial activity across cardiovascular, oncology, rare and genetic diseases (including the world’s primary Druze genetics research programme), mental health (PTSD, depression, substance use disorders), haematology, transplantation, and internal medicine; AUBMC’s institutional IRB; operating to US research ethics standards with an independent review process directly comparable to US academic medical centre IRBs; provides the most internationally recognised ethics governance of any Arab research hospital; AUBIO Biobank, the Arab world’s most properly governed research biobank, enables retrospective pharmacogenomic sub-studies within commercial trial programmes; the definitive institutional partner for any sponsor whose programmes require AUB’s specific combination of American-standard research governance, Arabic-speaking Levantine patient population, and access to the Druze genetic isolate through AUB’s established Chouf mountain community clinical outreach programme.
Lebanon’s premier Francophone academic hospital; affiliated with Université Saint-Joseph de Beyrouth (USJ, founded 1875 by Jesuits; French accreditation connections) and consistently ranked among Lebanon’s highest-quality hospitals; with Phase II–IV commercial research activity across oncology (one of Lebanon’s most active cancer research programmes, with Francophone oncology cooperative group connections), cardiovascular, neurology, haematology, and internal medicine; Hôtel-Dieu de France’s CEHDF ethics committee provides French-language ethics review aligned with French research ethics conventions for Francophone pharmaceutical company sponsors; the hospital’s primarily Francophone-Christian catchment from Beirut’s eastern Maronite and Greek-Catholic districts provides research access to a distinct Lebanese confessional-genetic demographic from the Hamra-district Arab Muslim and secular populations that dominate AUBMC’s catchment; an essential site for sponsors whose programmes use both US and French academic medical centre reference standards and who need to activate both AUB (anglophone-American) and HDF (Francophone) parallel institutional pathways in Beirut.
The primary teaching hospital of Lebanese American University (LAU); another NEASC-accredited American university in Beirut, providing a second American-standard academic medical research environment complementary to AUBMC; with Phase II–III commercial research activity across oncology (LAU’s cancer programme has been particularly active in breast cancer and gastrointestinal oncology research), cardiovascular, and internal medicine; LAU Medical Center’s commitment to Lebanese mental health research; including post-Beirut-blast PTSD studies, refugee mental health programmes, and substance use disorder research; has produced internationally published papers in Lancet Psychiatry, PLOS ONE, and other journals; LAU’s research programme benefits from its American accreditation’s IRB standards and its Lebanese diaspora network connections (LAU’s alumni and faculty include Lebanese-Americans at major US medical centres) that facilitate international research collaborations.
Beirut’s third major academic research hospital; affiliated with the University of Balamand (a Greek Orthodox institution with French and international academic connections) and one of Lebanon’s oldest and most respected hospitals; with Phase II–III research activity across cardiovascular, oncology, internal medicine, and nephrology; Saint George Hospital’s Achrafieh location serves Beirut’s Greek Orthodox and broader eastern Christian communities whose distinct Lebanese confessional-genetic profile creates pharmacogenomic research access to Levantine Mediterranean Christian genetic ancestry that is not the dominant demographic in AUB’s more heterogeneous Hamra catchment; Saint George Hospital University Medical Center’s affiliation with the University of Balamand and its connections to Greek Orthodox academic networks in Greece, Cyprus, and the wider Orthodox diaspora create international research partnership channels that complement the American-standard channels of AUB and LAU.
One of Beirut’s most internationally recognised private hospitals; JCI-accredited, located in the Clemenceau district between Hamra and Achrafieh; with Phase II–III commercial research activity across cardiovascular, oncology, metabolic disease, and internal medicine; Clemenceau Medical Center’s JCI accreditation and established multinational pharmaceutical company research relationships create a private hospital research environment whose quality management documentation standards and experienced research coordination team attract sponsors requiring Beirut private-sector research access beyond the university-affiliated public hospital networks; CMC’s patient catchment from Beirut’s mixed residential and diplomatic district; including Lebanese professionals, expatriate residents, and Arab medical tourists visiting Beirut (Lebanon retains significant medical tourism from Gulf countries and Iraq despite the economic crisis); provides enrollment access to a socioeconomic and nationally diverse patient demographic that differs from the primarily Lebanese-national public hospital catchments.
Lebanon’s primary public academic hospital; named after former Prime Minister Rafik Hariri and serving as the government’s national referral centre for complex cases and infectious disease; affiliated with the Lebanese University (LU) Faculty of Medicine and conducting Phase II–III research in infectious disease, internal medicine, and cardiovascular; RHUH’s location in Haret Hreik in Beirut’s southern suburbs; a predominantly Shia Muslim area that forms part of the Dahieh (southern suburb) demographic; provides research access to a distinct Lebanese confessional-community patient population whose genetic profile and healthcare utilisation patterns differ from those of Hamra and Achrafieh’s Christian-majority private hospital catchments; RHUH’s role as Lebanon’s national COVID-19 referral hospital during the pandemic produced internationally published COVID-19 clinical research, demonstrating the hospital’s capacity for rapid protocol implementation in crisis conditions.
Beirut’s largest Islamic welfare society hospital; operated by the Maqased Charitable Islamic Society and serving West Beirut’s predominantly Sunni Muslim community; with Phase II–III research activity across internal medicine, cardiovascular, paediatrics, and mental health; Makassed General Hospital’s Sunni Muslim community catchment provides research access to a distinct Lebanese confessional-genetic demographic; including families with origins in Tripoli, the Bekaa Valley, and southern Sunni communities; whose pharmacogenomic profile and healthcare-seeking patterns differ from the Shia Dahieh communities of RHUH or the Christian East Beirut communities of Hôtel-Dieu de France; Makassed’s mental health programme has been active in refugee mental health research, particularly given the hospital’s geographic proximity to Palestinian refugee camps (Shatila and Sabra) and its historical role serving displaced Lebanese and refugee communities.
LAU Medical Center’s northern Beirut campus; operating Saint John’s Hospital in Dora, the industrial suburb northeast of Beirut; and providing Phase II–III research access to the Armenian community concentration in Bourj Hammoud adjacent to Dora; Lebanese Armenians (~100,000 in Lebanon) represent one of the world’s most significant post-genocide founder-effect populations; descendants of survivors of the 1915 Armenian Genocide who settled in Lebanon after 1915–1923, forming a highly endogamous community in Bourj Hammoud whose genetic bottleneck has created elevated prevalence rates of specific rare conditions that AUB and Lebanese Armenian community organisations have begun characterising; LAU’s Saint John’s Hospital serves this community’s healthcare needs and provides a research access point for sponsors developing rare disease therapies where Armenian founder-effect genetics are a pharmacogenomically relevant consideration.
A major private hospital in Bsalim; in the Metn district of Mount Lebanon, northeast of Beirut; with Phase II–III commercial research activity across cardiovascular, oncology, and internal medicine; the Middle East Institute of Health’s Metn location provides research access to the Metn district’s predominantly Christian (Maronite and Greek Catholic) mountain communities whose distinct Lebanese confessional-genetic background and proximity to the Chouf mountains; where Lebanon’s Druze communities are concentrated; create research access to the Lebanese Druze-Christian Metn demographic corridor that approaches AUB’s Chouf outreach catchment from a Metn-side private hospital perspective; a well-equipped private hospital whose research office has managed commercial Phase II–III programmes across multiple therapeutic areas.
The university teaching hospital of Notre Dame University (NDU); a pontifical Catholic university affiliated with the Holy Spirit University of Kaslik; located in Jbeil (ancient Byblos), one of the world’s oldest continuously inhabited cities on Lebanon’s northern coast, and serving the Jbeil district’s predominantly Maronite Christian mountain and coastal communities; Phase II–III research activity across cardiovascular, internal medicine, and oncology; Notre Dame des Secours University Hospital’s northern coastal Maronite patient catchment; from the Jbeil, Batroun, and Koura communities whose distinctive Levantine Mediterranean Christian genetic ancestry has been maintained through high sectarian endogamy rates in Lebanon’s northern mountain villages; provides research access to a pharmacogenomically distinct Lebanese confessional-community sub-population that complements Beirut’s more demographically mixed urban patient catchments; its NDU academic affiliation and Catholic university international connections create research partnership channels with Catholic universities in France, Italy, and North America.
Tripoli’s major private hospital; serving Lebanon’s second-largest city (~250,000 population; predominantly Sunni Muslim; located 85 km north of Beirut near the Syrian border); with Phase II–III research activity across internal medicine, cardiovascular, and infectious disease; Al-Nini Hospital’s Tripoli location provides research access to northern Lebanon’s demographically distinct patient population; including Sunni Muslim communities from Tripoli’s historic port districts and the Akkar rural northern governorate; and is strategically positioned near the Syrian refugee concentrations of northern Lebanon’s Akkar and Bekaa border areas, where mental health, conflict-related NCD disruption, and infectious disease burden (including cutaneous leishmaniasis transmission from Syrian refugee-associated Phlebotomus sandfly spread) create refugee health research access complementary to Beirut’s urban research sites; northern Lebanon’s distinct Sunni and minority Christian communities provide a pharmacogenomically different Lebanese patient demographic from Beirut’s more heterogeneous urban mix.
A major private hospital in Jdeideh; the northern Beirut suburb adjacent to Bourj Hammoud’s Armenian quarter; with Phase II–III research activity across psychiatry, cardiovascular, and internal medicine; Hôpital du Sacré-Cœur’s psychiatric department; one of Lebanon’s most active inpatient and outpatient mental health treatment centres; provides research access to a large psychiatric patient population whose compound-crisis mental health burden (PTSD, depression, anxiety disorders, schizophrenia) reflects the full severity of Lebanon’s population-level mental health crisis; its Jdeideh location near the Armenian Bourj Hammoud community creates dual research access; to the psychiatric patient populations whose post-blast and post-crisis PTSD makes Lebanon’s mental health programme distinctive globally, and to the Lebanese Armenian community’s founder-effect genetic characteristics that are accessible through Sacré-Cœur’s Armenian-community catchment in Bourj Hammoud.
Lebanon’s Ministry of Public Health; the national authority for pharmaceutical product registration, clinical trial authorisation, and public health policy; operating under WHO GCP and ICH GCP E6(R2)-aligned regulations; MOPH’s Pharmaceutical Affairs Directorate manages clinical trial applications, which are processed in parallel with institutional IRB ethics approvals; MOPH accepts regulatory submissions in English, French, and Arabic; clinical trial approval timelines have historically been among the faster in the Arab world (1–3 months for standard Phase II–III applications), though the economic crisis has variably affected institutional function and sponsors should verify current processing timelines with experienced Lebanon CRO partners before submission planning; MOPH’s connections to WHO EMRO and its bilateral health cooperation agreements with France, WHO, and international health organisations provide the international regulatory alignment that supports cross-border trial data recognition.
Lebanon’s national medical professional regulatory body; governing physician licensure, continuing medical education, and research ethics oversight across Lebanon’s medical community; whose physician registration database and professional standards programme create the institutional framework within which commercial Phase II–III investigators are licensed and GCP-certified; OPL’s trilingual professional standards; operating in Arabic, French, and English reflecting Lebanon’s medical community’s trilingual professional culture; govern investigator qualifications across Lebanon’s diverse sectarian hospital network; OPL’s continuing medical education requirements ensure that Lebanese physician investigators maintain current GCP certification standards through internationally recognised CME programmes offered by AUB, USJ, LAU, and international pharmaceutical company education teams.
The MOPH directorate specifically responsible for pharmaceutical product registration and clinical trial authorisation; reviewing IND-equivalent applications, investigational medicinal product import permits, and protocol amendments under Lebanon’s clinical trial regulatory framework; the Directorate’s regulatory conventions reflect both French pharmaceutical regulatory influence (from Lebanon’s French-mandate institutional legacy) and American GCP standards (from AUB’s influence on Lebanese medical research culture), creating a bilingual French-English regulatory environment that is compatible with both EU and US pharmaceutical regulatory documentation standards; sponsors should work through experienced MENA CRO partners for MOPH submission preparation, particularly given the administrative challenges posed by Lebanon’s ongoing institutional crisis context.
The Arab world’s most internationally credentialed academic research hospital; NEASC-accredited, NIH-funded, and publishing in NEJM, Lancet, and JAMA; whose Clinical Research Unit manages Phase I–IV commercial and investigator-initiated trial portfolios across cardiovascular, oncology, rare genetic diseases (Druze genetics programme), mental health (post-blast PTSD; refugee mental health), haematology, and transplantation; AUBMC’s IRB is the most internationally recognised research ethics body in the Arab world outside Israel’s major medical centres; the AUBIO Biobank provides retrospective pharmacogenomic sub-study capabilities for commercial trial programmes; AUBMC’s diaspora research network; connecting Beirut investigators to Lebanese-American faculty at Harvard, Columbia, Johns Hopkins, and other US institutions; facilitates the international research collaborations through which multinational pharmaceutical companies engage the Lebanese academic investigator community.
Lebanon’s premier Francophone medical institution; Université Saint-Joseph (founded 1875, Jesuit; French accreditation connections) and its Hôtel-Dieu de France teaching hospital; conducting Phase II–IV research in oncology, cardiovascular, neurology, and internal medicine through Francophone oncology cooperative group connections and French/Belgian pharmaceutical company research partnerships; USJ’s CEHDF ethics committee provides French-language ethics review aligned with French research ethics conventions; USJ’s French university academic network connections; with Paris V, Paris VI, and Belgian Catholic universities; create the Francophone research partnership channels through which French, Belgian, and Swiss pharmaceutical companies most naturally engage the Lebanese academic investigator community.
One of the Arab world’s very few properly governed, ethics-approved, and internationally connected research biobanks; established at the American University of Beirut under the NIH-standard research governance framework of AUB’s IRB; storing biological samples (blood, plasma, DNA, tissue) from Lebanese citizens with full informed consent for specific and future research use; AUBIO’s sample collection spans Lebanon’s confessional diversity; including Druze, Maronite, Sunni Muslim, Shia Muslim, Greek Orthodox, and Armenian community donors; creating the pharmacogenomic diversity panel that makes retrospective genetic sub-studies within commercial AUB-site Phase II–III programmes feasible; AUBIO’s international connections to the BBMRI (Biobanking and BioMolecular Resources Research Infrastructure) European biobank network and NIH-funded biobank consortia provide the data-sharing infrastructure that enables Lebanese pharmacogenomic data to be integrated into international multi-ancestry research programmes.
Lebanese American University’s medical research infrastructure; operating Rizk Hospital in Hamra and Saint John’s Hospital in Dora under NEASC-accredited American standards; conducting Phase II–III research across oncology, cardiovascular, mental health (post-blast PTSD; refugee mental health; LAU’s School of Medicine has published extensively on Lebanese mental health in Lancet Psychiatry, PLOS ONE, and Substance Abuse Treatment journals), and internal medicine; LAU’s diaspora alumni network; including Lebanese-American physicians at US cancer centres and academic medical institutions; provides research partnership channels complementary to AUB’s; LAU’s American accreditation and IRB standards make it the second-most-internationally-recognised institutional research partner for anglophone pharmaceutical company sponsors considering multi-site Lebanese Phase II–III programmes.
Global CRO with Lebanon operations managed through its MENA network; supporting Phase II–IV programmes across cardiovascular, oncology, mental health (PTSD; post-blast research), metabolic disease, and rare disease indications; MOPH regulatory submission expertise and AUB/USJ/LAU IRB ethics application support in English, French, and Arabic; established investigator relationships across AUBMC, Hôtel-Dieu de France, LAU Medical Center, and the Beirut private hospital cluster; USD-denominated financial management through non-Lebanese banking channels; essential operational capability given Lebanon’s banking crisis; with experienced Lebanon-specific financial logistics that sponsors require for operational stability in the current crisis context; MENA regional coordination integrating Lebanon with Jordan, Egypt, and Morocco within integrated Arab-market Phase III programmes.
International biopharmaceutical solutions company with Lebanon operations providing integrated Phase II–IV clinical development services across cardiovascular, oncology, mental health, and rare disease indications; trilingual clinical operations capability (Arabic, French, English) matching Lebanon’s research environment uniquely; a specific Syneos Francophone-anglophone MENA capability that matches Lebanon’s dual French-USJ and English-AUB research cultures within a single CRO operational team; AUB IRB and USJ CEHDF ethics committee navigation expertise; USD cash management experience for Lebanon’s crisis financial environment; Druze community outreach coordination for rare disease trial feasibility in Lebanon’s Chouf mountain communities through AUB’s established clinical network.
Global CRO with Lebanon operations providing Phase II–III trial management and MOPH regulatory strategy across cardiovascular, oncology, mental health, and metabolic disease; established investigator and site management relationships across AUBMC, Hôtel-Dieu de France, Clemenceau Medical Center, and LAU Medical Center in Beirut; trilingual regulatory submission capability (English, French, Arabic) for MOPH authorisation and parallel AUB and USJ IRB ethics review; biostatistics and data management for Lebanese multi-confessional-community pharmacogenomic sub-group analyses; MENA regional programme coordination integrating Lebanon with Jordan, Egypt, and Tunisia within integrated Arab-market Phase III designs.
Several regional Levantine and MENA CROs maintain Lebanon-specific operations staffed by experienced Lebanese clinical research professionals; including former AUB and LAU research coordinators with established AUBMC, Hôtel-Dieu de France, and Clemenceau Medical Center site relationships; providing local regulatory navigation, USD cash management, investigator relationship management, and MOPH submission support that the institutional knowledge of Lebanon’s crisis operating environment requires; these Lebanon-experienced regional CRO teams provide the on-the-ground operational expertise that global CROs’ Lebanon desks may lack, and are essential for sponsors whose first-in-Lebanon site activation benefits from local institutional knowledge of MOPH’s current processing timelines, hospital administration channels, and the practical financial logistics of operating in USD in Lebanon’s dollarised crisis economy.
Lebanon is the Arab world’s most intellectually sophisticated and internationally connected research market; a country of 5.5 million that carries research impact per capita that rivals countries ten times its size, through AUB’s American-standard NIH-funded academic medical centre, the only trilingual (Arabic, French, English) investigator community in the Arab world, the globally significant Druze genetic isolate accessible through no other Arab institution at American-standard quality, and the world’s most intensively studied compound-crisis mental health population. The AUB argument is Lebanon’s most operationally powerful: unlike Cleveland Clinic Abu Dhabi (which is operated by Cleveland Clinic but in a Gulf context with Gulf patient populations), AUB is an endogenous Arab world institution; founded in 1866, rooted in Lebanese society, treating Lebanese patients from all 18 confessional communities; whose American academic accreditation, NIH funding portfolio, GCP-standard IRB, and AUBIO Biobank create research data quality directly comparable to Johns Hopkins or Columbia in patient populations that Johns Hopkins and Columbia cannot access. The mental health argument is Lebanon’s most scientifically irreplaceable: no other country in the Arab world; or arguably the world; provides access to a civilian population that has experienced civil war, assassination campaigns, multiple military invasions, a refugee crisis, economic collapse, a catastrophic explosion, and a pandemic in a single lifetime, all documented through the internationally published research of AUB, LAU, and their collaborating global institutions; for sponsors developing PTSD medications, antidepressants, anxiety treatments, or substance use disorder therapeutics who need Arabic-speaking Levantine population data from an authentically compound-crisis cohort, Lebanon is without equivalent. The Druze argument is Lebanon’s most pharmacogenomically distinctive: approximately 250,000 people in the Chouf mountains carrying LGMD2B (dysferlin mutation) at the world’s highest prevalence, LMNA cardiomyopathy variants, and novel recessive conditions characterised in AUB genetics publications; an endogamous genetic isolate of global scientific significance whose clinical research access requires AUBMC’s established Chouf community clinical programme. The operational context is real and must be planned for: USD cash management through non-Lebanese banking, institutional variability at public hospitals, and the ongoing political uncertainty of Lebanon’s crisis environment all require experienced Lebanon-CRO operational management. Sponsors who make that investment access one of the Arab world’s most scientifically rich, linguistically accessible, and institutionally credentialed research environments; an environment where the investigator can send a protocol query to AUBMC in English, discuss it with Hôtel-Dieu colleagues in French, explain it to Druze Chouf mountain patients in Arabic, and document it to standards that FDA reviewers accept without question.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.